Floatz logo

Ont-10

Advanced Ovarian Carcinoma

Cascadian Therapeutics Inc.Phase 1Dormant
CC
46/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
89/ 100

Competitive context

32 Active assets in the Advanced Ovarian Carcinoma cohort.

Asset / SponsorPhaseRating
Irinotecan
OHSU Knight Cancer Institute
Phase 2BB
TAMOXIFEN
OHSU Knight Cancer Institute
Phase 3BB
Bms-907351
M.D. Anderson Cancer Center
Phase 2BB
Capecitabine
OHSU Knight Cancer Institute
Phase 3BB
Abemaciclib
OHSU Knight Cancer Institute
Phase 2BB

View all 33 →

Same molecule, other indications

Ont-10 is also rated in:

Advanced Breast CarcinomaDormant
CC
Indicative ·
46 / 100
View asset →
neoplasmDormant
CC
Indicative ·
44 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →